Short latency and consistency in tumor development has made the PTEN-KO mouse model a useful tool to study the direct antitumor activity of novel agents and characterize pertinent molecular mechanisms during the early stage of prostate cancer development [17, 20, 21]. This evidence concerns the gene PTEN and prostate carcinoma.